1. Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission
by Sumithira Vasu, Jessica Kohlschmidt, Krzysztof Mrózek, Ann-Kathrin Eisfeld, Deedra Nicolet, Lisa J. Sterling, Heiko Becker, Klaus H. Metzeler, Dimitrios Papaioannou, Bayard L. Powell, Jonathan E. Kolitz, Joseph O. Moore, Maria R. Baer, Gail J. Roboz, Richard M. Stone, John C. Byrd, Andrew J. Carroll, and Clara D. Bloomfield
BloodAdv
Volume 2(13):
July 10, 2018
© 2018 by The American Society of Hematology

2. Sumithira Vasu et al. Blood Adv 2018;2:1645-1650
© 2018 by The American Society of Hematology

3. Overview of AML patients enrolled on the CALGB 8461 cytogenetic study and receiving chemotherapy-based treatment on successive CALGB trials.
Overview of AML patients enrolled on the CALGB 8461 cytogenetic study and receiving chemotherapy-based treatment on successive CALGB trials. Abnormal karyotype indicates other abnormal karyotypes (excluding CBF-AML); unknown karyotype (due to inadequate mitoses). APL, acute promyelocytic leukemia; CALGB, Cancer and Leukemia Group B; CBF, core-binding factor; CN, cytogenetically normal; sAML, secondary AML; tAML, therapy-related AML.
Sumithira Vasu et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology